glp 1 news Science's 2023 Breakthrough: GLP-1 Agonists Show Promise Against Obesity-Associated Disease Live webinar to discuss GLP-1

Patients often report nausea, vomiting, bloating, or bowel changes early in treatment

What matters most is that the prescribing clinician has experience managing obesity as a chronic disease and can follow you over time

The field of GLP-1 medications continues to evolve rapidly

In some of the trials, we saw that individuals who had those variants were unable to lower their blood glucose levels as effectively after six months of treatment, said Anna Gloyn, DPhil, professor of pediatrics and of genetics, and one of the studys senior authors

While formulations differ in dosing frequency, onset, and tolerability, they show broadly comparable safety and efficacy

Similar to alcohol, tobacco smoking is another leading cause of premature death